Prevention of recurrent lower urinary tract infections in postmenopausal women with genitourinary syndrome: outcome after 6 months of treatment with ospemifene. (1st February 2018)

• Record Type: Journal Article
• Authors: Schiavi, Michele Carlo; Di Pinto, Anna; Sciuga, Valentina; Faiano, Pierangelo; Di Tucci, Chiara; D'oria, Ottavia; Martoccia, Angela; Prata, Giovanni; Carraro, Carlo; Ostuni, Rosa; Zullo, Marzio Angelo; Muzii, Ludovico; Benedetti Panici, Pierluigi
• Is Part Of: Gynecological endocrinology. Volume 34:Number 2(2018)
• Page Start: 140
• Page End: 143
• Publication Date: 2018-02-01
• Subjects: Vulvovaginal atrophy -- recurrent lower urinary tract infections -- ospemifene -- menopause -- quality of life; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.1080/09513590.2017.1370645
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: Aim of this study was to evaluate the efficacy of ospemifene in the prevention of recurrent lower urinary tract infections in postmenopausal women with vulvovaginal atrophy. The study have a retrospective design. Thirty-nine patients were enrolled. Patients underwent clinical examination and urine culture. The urinary symptoms and the quality of life were evaluated with UTISA score, PUF and SF-36 questionnaires before and after treatment. All 39 patients received ospemifene 60 mg one tablet/daily for 6 months. Adverse effects and complications were assessed. Thirty-nine patients were enrolled in the study. Two patients experienced one new UTI episode and the mean number of positive urine culture decreased significantly after 6 months (3.65 ± 2.12 vs 0.25 ± 0.17, p < .0001). The mean number of urinary infection symptoms decreased significantly after treatment; dysuria reduced (4.76 ± 2.45 vs 0.89 ± 1.12). PUF score and SF-36 showed a statistically significant change (22.43 ± 5.89 vs 12.14 ± 3.21) and (52.86 ± 9.21 vs 83.43 ± 10.76). No adverse effects were reported and the total success rate was the 92.3% after 6 months at PGI-I. Ospemifene is a valid alternative with excellent tolerability for the UTIS prevention in postmenopausal patients.